Alvaro Alonso1, Jeffrey R Misialek1, Mohamed A Amiin1, Ron C Hoogeveen2, Lin Y Chen3, Sunil K Agarwal4, Laura R Loehr5, Elsayed Z Soliman6, Elizabeth Selvin7. 1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minneapolis, USA. 2. Department of Medicine, Baylor College of Medicine and Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. 3. Division of Cardiology, University of Minnesota Medical School, Minneapolis, Minneapolis, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Department of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. 6. Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Elevated levels of circulating liver enzymes have been associated with increased risk of cardiovascular disease. Their possible association with atrial fibrillation (AF) has received little attention. METHODS: We studied 9333 men and women, aged 53-75 years, free of AF, participating in the Atherosclerosis Risk in Communities Study followed-up from 1996 to 2010. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ glutamyl transpeptidase (GGT) were measured in stored plasma samples. Incident AF was ascertained from hospitalisations and death certificates. Associations between liver enzymes and AF incidence were assessed using multivariable Cox proportional hazards models. RESULTS: During a mean follow-up of 12 years, 1021 incident AF events were identified. Levels of AST, and to a lesser extent ALT, showed a U-shaped association with AF risk, with higher AF risk among individuals in the two extremes of the distribution in minimally adjusted models. The associations were weakened after adjustment for potential confounders. By contrast, GGT, modelled as log base 2, was linearly associated with AF risk after multivariable adjustment: a doubling of GGT levels was associated with a 20% increased risk of AF (95% CI 10% to 30%). Additional adjustment for inflammatory markers did not appreciably affect the results. Associations were not different in men and women, in whites and blacks, among never drinkers of alcohol, and among those without prevalent heart failure. CONCLUSIONS: In this community-based prospective study, higher levels of liver enzymes, mainly GGT, were associated with an increased risk of AF. The mechanisms underlying this association deserve further scrutiny. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Elevated levels of circulating liver enzymes have been associated with increased risk of cardiovascular disease. Their possible association with atrial fibrillation (AF) has received little attention. METHODS: We studied 9333 men and women, aged 53-75 years, free of AF, participating in the Atherosclerosis Risk in Communities Study followed-up from 1996 to 2010. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ glutamyl transpeptidase (GGT) were measured in stored plasma samples. Incident AF was ascertained from hospitalisations and death certificates. Associations between liver enzymes and AF incidence were assessed using multivariable Cox proportional hazards models. RESULTS: During a mean follow-up of 12 years, 1021 incident AF events were identified. Levels of AST, and to a lesser extent ALT, showed a U-shaped association with AF risk, with higher AF risk among individuals in the two extremes of the distribution in minimally adjusted models. The associations were weakened after adjustment for potential confounders. By contrast, GGT, modelled as log base 2, was linearly associated with AF risk after multivariable adjustment: a doubling of GGT levels was associated with a 20% increased risk of AF (95% CI 10% to 30%). Additional adjustment for inflammatory markers did not appreciably affect the results. Associations were not different in men and women, in whites and blacks, among never drinkers of alcohol, and among those without prevalent heart failure. CONCLUSIONS: In this community-based prospective study, higher levels of liver enzymes, mainly GGT, were associated with an increased risk of AF. The mechanisms underlying this association deserve further scrutiny. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Abigail Fraser; Ross Harris; Naveed Sattar; Shah Ebrahim; George Davey Smith; D A Lawlor Journal: Arterioscler Thromb Vasc Biol Date: 2007-10-11 Impact factor: 8.311
Authors: F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi Journal: J Clin Endocrinol Metab Date: 2004-12-14 Impact factor: 5.958
Authors: A D White; A R Folsom; L E Chambless; A R Sharret; K Yang; D Conwill; M Higgins; O D Williams; H A Tyroler Journal: J Clin Epidemiol Date: 1996-02 Impact factor: 6.437
Authors: Christopher W Seymour; Colin R Cooke; Zheyu Wang; Kathleen F Kerr; Donald M Yealy; Derek C Angus; Thomas D Rea; Jeremy M Kahn; Margaret S Pepe Journal: J Crit Care Date: 2013-04-06 Impact factor: 3.425
Authors: M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin Journal: J Endocrinol Invest Date: 2017-11-30 Impact factor: 4.256
Authors: Antonio P Arenas de Larriva; Faye L Norby; Lin Y Chen; Elsayed Z Soliman; Ron C Hoogeveen; Dan E Arking; Laura R Loehr; Alvaro Alonso Journal: Int J Cardiol Date: 2017-04-06 Impact factor: 4.164
Authors: Jelena Kornej; Vanessa A Hanger; Ludovic Trinquart; Darae Ko; Sarah R Preis; Emelia J Benjamin; Honghuang Lin Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 10.787
Authors: Yifei Lu; James R Pike; Elizabeth Selvin; Thomas Mosley; Priya Palta; A Richey Sharrett; Alvin Thomas; Laura Loehr; A Sidney Barritt; Ron C Hoogeveen; Gerardo Heiss Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.160